Close Menu

NEW YORK (GenomeWeb) – US Oncology Network has selected Myriad Genetics Laboratories as its preferred provider of hereditary cancer genetic testing.

Myriad Genetics said it will provide testing through the Genetic Risk Evaluation and Testing (GREAT) program, which will be accessible to 800,000 patients who each year receive care from the more than 1,000 community physicians across 350 sites within US Oncology Network.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.